Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma
Author:
Affiliation:
1. Lymphoma Service of the Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY; and
2. Hematologic Malignancies, Lahey Clinic Medical Center, Burlington, MA
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/116/23/4934/1333878/zh804910004934.pdf
Reference14 articles.
1. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.;Linch;Lancet,1993
2. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.;Schmitz;Lancet,2002
3. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.;Moskowitz;Blood,2001
4. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.;Sirohi;Annals of Oncology,2008
5. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.;Hutchings;Blood,2006
Cited by 211 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. What is the best salvage therapy for Hodgkin lymphoma?;Current Opinion in Oncology;2024-06-20
2. The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era;Seminars in Hematology;2024-06
3. Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial;BMC Medicine;2024-03-07
4. Very late relapse in Hodgkin lymphoma: Characterizing an understudied population;Clinical Lymphoma Myeloma and Leukemia;2023-11
5. Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy;Cancers;2023-09-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3